Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Children's Oncology Group

Status: Completed

Conditions: Childhood Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission

Treatments: Other: Laboratory Biomarker Analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01024127

CDR0000660540 (Other Identifier)

COG-AAML10B11 (Other Identifier)

NCI-2011-02202 (Registry Identifier)

AAML10B11 (Other Identifier)

Details and patient eligibility

About

This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

Full description

PRIMARY OBJECTIVES:

l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML) relapse and infection risk.

II. Validate positive associations seen in the genome-wide scan with a fine mapping approach.

III. Perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with AML.

OUTLINE:

Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.

Enrollment: 2,500 estimated patients

Sex: All

Ages: Under 30 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of AML

  • In remission

• Adequate DNA from peripheral blood or bone marrow samples

• Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97, AML-04,AML-09, or Canada AML Infection clinical trial required

Trial design

2,500 participants in 1 patient group

Ancillary-correlative (predictors of AML treatment outcomes)

Description:

Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.

Treatment:

Other: Laboratory Biomarker Analysis